VNDA Vanda Pharmaceuticals Inc
Price (delayed)
$4.85
Market cap
$282.83M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.33
Enterprise value
$188.61M
Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients.
Highlights
The gross profit has increased by 5% YoY and by 4.9% from the previous quarter
The revenue has increased by 4.1% QoQ and by 3.2% YoY
VNDA's debt is up by 47% since the previous quarter and by 15% year-on-year
VNDA's net income is down by 15% since the previous quarter
Key stats
What are the main financial stats of VNDA
Market
Valuations
Earnings
Shares outstanding
58.32M
Market cap
$282.83M
Enterprise value
$188.61M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.53
Price to sales (P/S)
1.42
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.95
Revenue
$198.77M
Gross profit
$187.46M
Operating income
-$40.66M
Net income
-$18.9M
EBIT
-$22.92M
EBITDA
-$14.79M
Free cash flow
-$16.25M
Per share
Balance sheet
Liquidity
EPS
-$0.33
EPS diluted
-$0.33
Free cash flow per share
-$0.28
Book value per share
$9.24
Revenue per share
$3.42
TBVPS
$9.32
Total assets
$656.2M
Total liabilities
$117.66M
Debt
$8.09M
Equity
$538.55M
Working capital
$338.91M
Debt to equity
0.02
Current ratio
4.39
Quick ratio
4.22
Net debt/EBITDA
6.37
Margins
Efficiency
Dividend
EBITDA margin
-7.4%
Gross margin
94.3%
Net margin
-9.5%
Operating margin
-20.5%
Return on assets
-2.9%
Return on equity
-3.5%
Return on invested capital
-6.8%
Return on capital employed
-4.1%
Return on sales
-11.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
VNDA stock price
How has the Vanda Pharmaceuticals stock price performed over time
Intraday
-1.22%
1 week
1.89%
1 month
1.04%
1 year
26.96%
YTD
1.25%
QTD
1.25%
Financial performance
How have Vanda Pharmaceuticals's revenue and profit performed over time
Revenue
$198.77M
Gross profit
$187.46M
Operating income
-$40.66M
Net income
-$18.9M
Gross margin
94.3%
Net margin
-9.5%
The operating income has plunged by 191% YoY and by 8% from the previous quarter
VNDA's operating margin has shrunk by 185% YoY and by 4.6% QoQ
VNDA's net income is down by 15% since the previous quarter
VNDA's net margin is down by 10% since the previous quarter
Growth
What is Vanda Pharmaceuticals's growth rate over time
Valuation
What is Vanda Pharmaceuticals stock price valuation
P/E
N/A
P/B
0.53
P/S
1.42
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.95
The company's EPS fell by 14% QoQ
VNDA's P/B is 52% below its 5-year quarterly average of 1.1 but 6% above its last 4 quarters average of 0.5
VNDA's P/S is 35% below its 5-year quarterly average of 2.2 and 5% below its last 4 quarters average of 1.5
The revenue has increased by 4.1% QoQ and by 3.2% YoY
Efficiency
How efficient is Vanda Pharmaceuticals business performance
Vanda Pharmaceuticals's ROIC has decreased by 24% from the previous quarter
The company's return on sales fell by 21% QoQ
Vanda Pharmaceuticals's return on equity has decreased by 17% QoQ
Vanda Pharmaceuticals's ROA has decreased by 16% from the previous quarter
Dividends
What is VNDA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for VNDA.
Financial health
How did Vanda Pharmaceuticals financials performed over time
VNDA's total liabilities is up by 14% YoY and by 13% QoQ
VNDA's quick ratio is down by 12% YoY and by 10% from the previous quarter
VNDA's debt is 98% smaller than its equity
Vanda Pharmaceuticals's debt to equity has soared by 100% from the previous quarter and by 100% YoY
VNDA's debt is up by 47% since the previous quarter and by 15% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.